Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Nausea And Vomiting Treatment Market by Type (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen), By Application (CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Nausea And Vomiting Treatment Market by Type (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen), By Application (CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 171378 3300 Pharma & Healthcare 377 239 Pages 5 (44)
                                          

Market Overview:


The global nausea and vomiting treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market was valued at USD 2,362.8 million in 2018 and is projected to reach USD 3,471.1 million by 2030. Serotonin receptor antagonist had the biggest market share of 61% in 2018 while neurokinin NK1 receptor antagonist had the second-biggest share of 18%. In terms of application, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018. North America has been leading the global nausea and vomiting treatment market since 2017 and is expected to continue its dominance during the forecast period as well (2018-2030).


Global Nausea And Vomiting Treatment Industry Outlook


Product Definition:


Nausea and vomiting are common symptoms of many diseases and conditions. Nausea is a sensation that often precedes vomiting. It is an uneasiness or discomfort in the stomach that may lead to vomiting. Vomiting, also called emesis, is the act of throwing up or regurgitating food and/or liquid from the stomach.


Serotonin Receptor Antagonist:


According to the National Institute of Mental Health, approximately 15.0 million adults in the U.S. have been diagnosed with major depression in 2016 and 7.0 million have been treated with medication only to discover that this is not a permanent cure but rather a chronic condition that requires continuous monitoring and management which leads to high demand for various anti-depressant drugs over the counter (OTC) medications used for its treatment such as selective serotonin receptor antagonists (SSRIs).


Neurokinin NK1 Receptor Antagonist:


Neurokinin NK1 receptor antagonist is a type of drug that works by blocking the action of neurokinin (NKR) receptors, which are present on nerve cells in the brain stem. Blocking these receptors prevents nausea and vomiting.


Application Insights:


PONV is the second-largest application of nausea and vomiting treatments, with a share of 30.4% in 2018. The rising prevalence of PONV due to various factors such as changes in climate, diet and alcohol intake is anticipated to boost the demand for these drugs over the forecast period., motion sicknessness is expected to be one of the fastest growing segments during the forecast period owing to increasing use in cruise ships and long haul flight., pregnancy related nausea and vomiting has become a common occurrence among women who are pregnant for 1st time or 2nd time. This has increased awareness about treatment options which may help drive growth., others include anxiety related nausea & vomiting caused due largely by environmental factors such as food allergies that may require medical consultation before treating with medication., CINV segment accounted for 49% share in 2018 owing largely on account increase incidence globally since last few years especially after 50 years old age group where prevalence rate increases exponentially thus driving market growth over next seven years.


Regional Analysis:


North America dominated the global market in 2018. This can be attributed to the high prevalence of functional gastrointestinal disorders, increasing awareness about available treatment options, and availability of highly effective drugs. Moreover, presence of key pharmaceutical companies that are engaged in strategic initiatives for development and commercialization of novel anti-nausea/vomiting drugs is also expected to drive regional growth over the forecast period.


Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period owing to rising geriatric population base coupled with increasing incidence rates for chronic diseases such as cancer., diabetes., Parkinson’s disease (PD), multiple sclerosis (MS) & other neurological disorders which result in PONV or nausea & vomiting attacks The prevalence rate for these conditions ranges from 7% - 10% among Asian population which is higher than that observed among white people (3%). These factors are contributing towards increased demand for nausea and vomiting treatments among patients from Asia Pacific region.


Growth Factors:


  • Rising incidence of nausea and vomiting across the globe
  • Increasing awareness about various nausea and vomiting treatments available in the market
  • Growing demand for minimally invasive procedures for treating nausea and vomiting
  • Technological advancements in the field of nausea and vomiting treatment therapies
  • Rising number of clinical studies on new drugs for treating nausea and vomiting

Scope Of The Report

Report Attributes

Report Details

Report Title

Nausea And Vomiting Treatment Market Research Report

By Type

Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen

By Application

CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.

By Companies

Merck & Co. Inc., Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro, Nausea And Vomiting Treatmen

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

239

Number of Tables & Figures

168

Customization Available

Yes, the report can be customized as per your need.


Global Nausea And Vomiting Treatment Market Report Segments:

The global Nausea And Vomiting Treatment market is segmented on the basis of:

Types

Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Merck & Co. Inc.
  2. Helsinn Group
  3. Unimed Pharmaceuticals (AbbVie Inc.)
  4. Kyowa Kirin
  5. Sanofi
  6. Qilu Pharma
  7. Teva Pharmaceutical Industries Ltd.
  8. Taiji group
  9. Novartis
  10. Heron Therapeutics
  11. Atnahs Pharma UK Limited
  12. Mylan
  13. Duchesnay
  14. Tesaro
  15. Nausea And Vomiting Treatmen

Global Nausea And Vomiting Treatment Market Overview


Highlights of The Nausea And Vomiting Treatment Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Serotonin Receptor Antagonist
    2. Neurokinin NK1 Receptor Antagonist
    3. Other
    4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
    5. Nausea And Vomiting Treatmen
  1. By Application:

    1. CINV
    2. PONV
    3. Motion Sickness
    4. Pregnancy
    5. Others
    6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Nausea And Vomiting Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Nausea And Vomiting Treatment Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Nausea and vomiting treatment is a combination of medications and lifestyle changes that are used to reduce the frequency, intensity, or both of nausea and vomiting. Treatment may also include rest, fluids, food replacement therapy, anti-nausea medications (such as prochlorperazine), and pain relief.

Some of the major players in the nausea and vomiting treatment market are Merck & Co. Inc., Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro, Nausea And Vomiting Treatmen.

The nausea and vomiting treatment market is expected to grow at a compound annual growth rate of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Nausea And Vomiting Treatment Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Nausea And Vomiting Treatment Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Nausea And Vomiting Treatment Market - Supply Chain
   4.5. Global Nausea And Vomiting Treatment Market Forecast
      4.5.1. Nausea And Vomiting Treatment Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Nausea And Vomiting Treatment Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Nausea And Vomiting Treatment Market Absolute $ Opportunity

5. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
      5.3.1. Serotonin Receptor Antagonist
      5.3.2. Neurokinin NK1 Receptor Antagonist
      5.3.3. Other
      5.3.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      5.3.5. Nausea And Vomiting Treatmen
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      6.3.1. CINV
      6.3.2. PONV
      6.3.3. Motion Sickness
      6.3.4. Pregnancy
      6.3.5. Others
      6.3.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026

9. North America Nausea And Vomiting Treatment Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      9.4.1. CINV
      9.4.2. PONV
      9.4.3. Motion Sickness
      9.4.4. Pregnancy
      9.4.5. Others
      9.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
      9.7.1. Serotonin Receptor Antagonist
      9.7.2. Neurokinin NK1 Receptor Antagonist
      9.7.3. Other
      9.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      9.7.5. Nausea And Vomiting Treatmen
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026

10. Latin America Nausea And Vomiting Treatment Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      10.4.1. CINV
      10.4.2. PONV
      10.4.3. Motion Sickness
      10.4.4. Pregnancy
      10.4.5. Others
      10.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
      10.7.1. Serotonin Receptor Antagonist
      10.7.2. Neurokinin NK1 Receptor Antagonist
      10.7.3. Other
      10.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      10.7.5. Nausea And Vomiting Treatmen
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026

11. Europe Nausea And Vomiting Treatment Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      11.4.1. CINV
      11.4.2. PONV
      11.4.3. Motion Sickness
      11.4.4. Pregnancy
      11.4.5. Others
      11.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Nausea And Vomiting Treatment Market Size and Vlume Forecast by Type
      11.7.1. Serotonin Receptor Antagonist
      11.7.2. Neurokinin NK1 Receptor Antagonist
      11.7.3. Other
      11.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      11.7.5. Nausea And Vomiting Treatmen
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Nausea And Vomiting Treatment Demand Share, 2019-2026

12. Asia Pacific Nausea And Vomiting Treatment Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      12.4.1. CINV
      12.4.2. PONV
      12.4.3. Motion Sickness
      12.4.4. Pregnancy
      12.4.5. Others
      12.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
      12.7.1. Serotonin Receptor Antagonist
      12.7.2. Neurokinin NK1 Receptor Antagonist
      12.7.3. Other
      12.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      12.7.5. Nausea And Vomiting Treatmen
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Nausea And Vomiting Treatment Demand Share, 2019-2026

13. Middle East & Africa Nausea And Vomiting Treatment Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
      13.4.1. CINV
      13.4.2. PONV
      13.4.3. Motion Sickness
      13.4.4. Pregnancy
      13.4.5. Others
      13.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
      13.7.1. Serotonin Receptor Antagonist
      13.7.2. Neurokinin NK1 Receptor Antagonist
      13.7.3. Other
      13.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
      13.7.5. Nausea And Vomiting Treatmen
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Nausea And Vomiting Treatment Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Nausea And Vomiting Treatment Market: Market Share Analysis
   14.2. Nausea And Vomiting Treatment Distributors and Customers
   14.3. Nausea And Vomiting Treatment Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Merck & Co. Inc.
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Helsinn Group
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Unimed Pharmaceuticals (AbbVie Inc.)
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Kyowa Kirin
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Sanofi
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Qilu Pharma
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Teva Pharmaceutical Industries Ltd.
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Taiji group
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Novartis
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Heron Therapeutics
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Atnahs Pharma UK Limited
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Mylan
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Duchesnay
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Tesaro
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Nausea And Vomiting Treatmen
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
  &n

Our Trusted Clients

Contact Us